Prometheus to Sell Rosetta Genomics' Tests; Takes Equity Stake

Prometheus will sell Rosetta's three microRNA-based tests and will invest $8 million in the molecular diagnostics firm.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.